Use of Ethinylestradiol/Drospirenone Combination in Patients with Polycystic Ovary Syndrome

April 2008 in “ Therapeutics and clinical risk management ”

Ruchi Mathur, О С Левин, Ricardo Azziz

ethinylestradiol drospirenone combined oral contraceptives COCs polycystic ovary syndrome PCOS hirsutism acne menstrual irregularities anti-androgenic properties carbohydrate metabolism lipid profiles birth control pills oral contraceptives

Studysummary This review covers the use of combined oral contraceptives, particularly drospirenone, for managing polycystic ovary syndrome and discusses related metabolic controversies without reporting new clinical results. Our plain-language summary of this paper — not a Tressless recommendation.

The study reviewed the use of combined oral contraceptives (COCs) containing ethinylestradiol and drospirenone in treating polycystic ovary syndrome (PCOS). It concluded that this combination was effective in managing PCOS symptoms such as hirsutism, acne, and menstrual irregularities, with a favorable safety profile. Clinical observations and data from studies involving 20 and 18 women showed significant improvements in symptoms and hormone levels over 6 months to 12 cycles. Drospirenone's anti-androgenic properties were particularly beneficial, and it had fewer metabolic side effects compared to other COCs. However, some concerns about effects on carbohydrate metabolism and lipid profiles were noted.

View this study on dovepress.com →

Discuss this study in the Community →

Research cited in this study

5 / 5 results

research Choice of Treatment for Women with Polycystic Ovary Syndrome

10 citations , June 2006 in “Fertility and Sterility”

This article discusses the diverse symptoms and treatment options for polycystic ovary syndrome, emphasizing diligent management of its metabolic component, but reports no new findings.

A Prospective Randomized Trial Comparing Low Dose Flutamide, Finasteride, Ketoconazole, and Cyproterone Acetate-Estrogen Regimens in the Treatment of Hirsutism

research A Prospective Randomized Trial Comparing Low Dose Flutamide, Finasteride, Ketoconazole, and Cyproterone Acetate-Estrogen Regimens in the Treatment of Hirsutism

113 citations , April 1999 in “The Journal of Clinical Endocrinology and Metabolism”

This study found that all four treatments—flutamide, finasteride, ketoconazole, and EE-CPA—significantly reduced hirsutism, but EE-CPA and flutamide appeared most effective, with varying effects on androgen levels and side-effect profiles.

research Prevalence of Polycystic Ovary Syndrome in Unselected Black and White Women of the Southeastern United States: A Prospective Study

633 citations , September 1998 in “The Journal of Clinical Endocrinology and Metabolism”

This study observed that among a cohort of reproductive-aged women in the U.S., the prevalence of PCOS was about 4.0%, with no significant racial differences between White and Black women.

research Cyproterone Acetate for Severe Hirsutism: Results of a Double-Blind Dose-Ranging Study

94 citations , July 1991 in “Clinical endocrinology”

In this study, cyproterone acetate at 2 mg daily was found to be as effective as higher doses in reducing hair growth for hirsute women over 12 months.

research Use of Cyproterone Acetate in the Treatment of Acne, Hirsutism, and Virilism

232 citations , June 1975 in “Journal of Steroid Biochemistry”

In this study, a treatment regimen combining cyproterone acetate and ethinyl estradiol significantly improved acne and seborrhoea in most women after three months, but had varied effects on hirsutism and alopecia.